flumazenil subcutaneous / Go Medical - LARVOL DELTA

Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification (ANZAC 2023) - "A growing body of evidence has suggested that low-dose flumazenil, a GABAA receptor antagonist, may be a useful agent to allow for rapid detoxification, with some preliminary data published on the likely mechanism of an anxiolytic action in anxiety disorders, which BZDs are commonly prescribed for.Study: We present pilot data on the safety and efficacy of low-dose subcutaneous flumazenil to reduce BZD use, withdrawal symptoms, and craving. In a randomised double-blinded crossover study design, participants received low-dose flumazenil first (4 mg/24 h for approximately eight days) or placebo; participants taking ≥ 30 mg diazepam equivalent at baseline (n = 15) significantly reduced diazepam use by 30.5% (p = 0.024) compared to placebo. Low-dose flumazenil may aid in BZD detoxification in participants taking daily diazepam equivalent doses ≥ to the therapeutic maximum (≥30 mg) by reducing the need for diazepam. Further research should compare abstinence rates after..."

Clinical • CNS Disorders • Mood Disorders • Psychiatry

Outcomes of patients treated with low-dose flumazenil for benzodiazepine detoxification: A description of 26 participants. (PubMed, Drug Alcohol Depend) - "Self-reported rates of abstinence from benzodiazepines at three months was between 46.2 % and 61.5 %. Flumazenil may yield greater success than benzodiazepine tapering from high dose benzodiazepine use (≥30 mg diazepam equivalent). Further research should compare abstinence rates after treatment with flumazenil compared to benzodiazepine tapering in high dose benzodiazepine users."

Journal • Psychiatry

A double-blind randomised crossover trial of low-dose flumazenil for benzodiazepine withdrawal: A proof of concept. (PubMed, Drug Alcohol Depend) - "Low-dose flumazenil may aid in BZD detoxification in participants taking daily diazepam equivalent doses greater than or equal to the therapeutic maximum (≥30 mg) by reducing the need for diazepam."

Journal

Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. (PubMed) - EJNMMI Res - "IDM improved quantitative accuracy of measured activity concentrations. Moreover, the use of IDM in combination with HYPR (Hypr-IDM-Hypr) was able to correct for PVE without increasing noise."

Journal • Alzheimer's Disease • Biosimilar